Search results
Your search for RYR3 returned no results
Showing 31 to 45 of 469 results for rare
Showing 31 to 45 of 469 results for rare
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
Evidence-based recommendations on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI in adults. This involves placing a device inside an artery near the heart.
View recommendations for HTG515Show all sections
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Phrenic nerve pacing for congenital central hypoventilation syndrome (HTG725)
Evidence-based recommendations on phrenic nerve pacing for congenital central hypoventilation syndrome. This involves direct stimulation of the phrenic nerve, to produce the inhalation phrase of breathing.
View recommendations for HTG725Show all sections
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
This indicator covers the percentage of patients aged 15 years and over who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM40
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351
In development Reference number: GID-TA11333 Expected publication date: TBC
In development Reference number: GID-HST10067 Expected publication date: 19 August 2026
Intramedullary distraction for upper limb lengthening (HTG621)
Evidence-based recommendations on intramedullary distraction for upper limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter arm.
View recommendations for HTG621Show all sections
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Evidence-based recommendations on percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum. This involves opening up the closed pulmonary valve of the babies heart while it is still in the womb using a balloon-like device.
View recommendations for HTG114Show all sections
Sections for HTG114
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.